NCT07618260招募中1 期
A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0613 in Participants With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 294
- 试验地点
- 1
- 主要终点
- Dose escalation: Safety and tolerability
研究概览
简要总结
This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic characteristics of SIM0613 in participants with locally advanced/ metastatic solid tumors. The study starts with a dose escalation part (Part 1) followed by a dose expansion part (Part 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent (ICF) is obtained prior to any of the specified procedures required for the study
- •≥18 years of age
- •Histologically or cytologically confirmed locally advanced/metastatic solid tumors
- •Have at least one measurable disease per RECIST Version 1.1 criteria
- •Have experienced disease progression on/after at least one accessible standard therapy, or are intolerant to standard therapy, or are not suitable for standard therapy, or for whom clinical trial of the investigational drug serves as standard treatment
- •Life expectancy of ≥12 weeks
- •Have adequate organ function
- •Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to the start of study treatment.
- •For Part 1, archival or fresh tumor tissue sample (preferably 12 with a minimum number of 10 sections) should be collected if available at Biomarker-screening or screening visit. For Part 2, it is mandatory to collect archival tumor tissue sample (preferably 12 with a minimum number of 10 sections) performed within 6 months prior to consent or fresh tumor tissue sample at Biomarker-screening or screening visit
排除标准
- •Any other malignancy within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence (e.g., basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast)
- •Participants with symptomatic central nervous system (CNS) metastases, or CNS metastases requiring CNS-directed local therapy (such as radiotherapy or surgery), or CNS metastases requiring corticosteroids therapy within 2 weeks of first dose of study treatment.
- •History of bowel obstruction within 3 months prior to the first dose of study treatment.
- •Known psychiatric disorder or drug abuse that would interfere the study requirements
- •Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment
- •Any active infection requires systemic treatment via intravenous infusion within 2 weeks prior to the first dose of study treatment
- •Has not recovered (i.e., to Grade 1 or to baseline) from previous anticancer therapy-induced AEs.
- •Participant is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of SIM
- •Major surgery within 2 weeks of receiving the first dose of study treatment (minor procedures such as mediastinoscopy, insertion of a central venous access device, insertion of a feeding tube, needle biopsy and percutaneous nephrostomy are not considered major surgery)
- •Prior exposure to topoisomerase I (TOP-I) inhibitor inhibitor-based antibody-drug conjugate (ADC) therapies or LRRC15-targeted therapies.
- •Use of any live vaccine therapy within 4 weeks prior to the first dose of study treatment
- •Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS)
- •Active hepatitis B (HBsAg or HBcAb positive）
- •History of allogeneic organ transplantation or graft-versus-host disease
- •Known hypersensitivity to study drug or any of the excipients
- •Participant is pregnant or breastfeeding
- •Other conditions that researchers consider inappropriate for inclusion.
研究组 & 干预措施
A dose escalation of SIM0613
Experimental
干预措施: SIM0613 (Drug)
A dose expansion of SIM0613 in several different solid tumors
Experimental
干预措施: SIM0613 (Drug)
结局指标
主要结局
Dose escalation: Safety and tolerability
时间窗: 2 years
Safety and tolerability：Number of participants with treatment-related adverse events as assessed by CTCAE v6.0，including laboratory values, vital signs, and electrocardiograms (ECGs), etc；AE related dose modifications(interruption, reduction and discontinuation) , etc
Dose escalation：Dose -limiting toxicity (DLT)
时间窗: The first 21 days after the first dose of study treatment
Dose expansion：Objective response rate(ORR)
时间窗: 2 years
Proportion of subjects who have a complete or partial response assessed by investigator per RECIST 1.1
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
First in Human Study of SIM0610 in Solid TumorsColorectal CancerHepatocellular CarcinomaNon-Small Cell Lung CancerAdvanced Solid TumoursHead and Neck Squamous Cell CarcinomaNCT07348211Jiangsu Simcere Pharmaceutical Co., Ltd.260
招募中
1 期
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsAdvanced Solid TumorsNCT07360314EMD Serono Research & Development Institute, Inc.138
尚未招募
不适用
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsAdvanced Solid TumorsNCT07311603Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany138
招募中
1 期
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPolycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Post-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis (PMF)NCT07469891Prelude Therapeutics Incorporated100
尚未招募
1 期
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant TumorsAdvanced Solid Tumor MalignanciesNCT07475559Jiangsu Alphamab Biopharmaceuticals Co., Ltd42